Cargando…

Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL-mediated NF-κB and JNK and their downstream signalling pathways

Targeting excessive osteoclast differentiation and activity is considered a valid therapeutic approach for osteoporosis. Zoledronic acid (ZOL) plays a pivotal role in regulating bone mineral density. However, the exact molecular mechanisms responsible for the inhibitory effects of ZOL on receptor ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Xiao-Lin, Liu, Chao, Shi, Xue-Mei, Cheng, Yu-Ting, Zhou, Qian, Li, Jian-Ping, Liao, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711024/ https://www.ncbi.nlm.nih.gov/pubmed/34935053 http://dx.doi.org/10.3892/mmr.2021.12575

Ejemplares similares

Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways
por: van Heerden, Bernadette, et al.
Publicado: (2017)

Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption
por: Niu, Chenguang, et al.
Publicado: (2017)

Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation
por: Zhang, Qiang, et al.
Publicado: (2018)

Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption
por: Shang, Nan, et al.
Publicado: (2019)

Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB
por: Quan, Gui-Hua, et al.
Publicado: (2015)

C-phycocyanin attenuates RANKL-induced osteoclastogenesis and bone resorption in vitro through inhibiting ROS levels, NFATc1 and NF-κB activation
por: AlQranei, Mohammed S., et al.
Publicado: (2020)

Bushen huoxue decoction inhibits RANKL-stimulated osteoclastogenesis and glucocorticoid-induced bone loss by modulating the NF-κB, ERK, and JNK signaling pathways
por: Liu, Yamei, et al.
Publicado: (2022)

Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression
por: Lin, Wei, et al.
Publicado: (2021)

Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages
por: Jin, Gu, et al.
Publicado: (2018)

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities
por: Joung, Youn Hee, et al.
Publicado: (2016)

Galangin suppresses RANKL‐induced osteoclastogenesis via inhibiting MAPK and NF‐κB signalling pathways
por: Li, Xiucheng, et al.
Publicado: (2021)

Protaetia brevitarsis Extract Attenuates RANKL-Induced Osteoclastogenesis by Inhibiting the JNK/NF-κB/PLCγ2 Signaling Pathway
por: Jang, Hye-Yeon, et al.
Publicado: (2023)

Corrigendum: Bushen huoxue decoction inhibits RANKL-stimulated osteoclastogenesis and glucocorticoid-induced bone loss by modulating the NF-κB, ERK, and JNK signaling pathways
por: Liu, Yamei, et al.
Publicado: (2023)

Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways
por: Huang, Xiao-Lin, et al.
Publicado: (2019)

Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
por: Zhu, Mengbo, et al.
Publicado: (2021)

Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity
por: Lee, Jin-Young, et al.
Publicado: (2021)

Casticin suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating the AKT/ERK and NF-κB signaling pathways
por: Yang, Fan, et al.
Publicado: (2023)

Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells
por: Zeng, Yan-Ping, et al.
Publicado: (2016)

Sphingosine-1-Phosphate Receptor 2 Controls Podosome Components Induced by RANKL Affecting Osteoclastogenesis and Bone Resorption
por: Hsu, Li-Chien, et al.
Publicado: (2019)

Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
por: Guo, Wen, et al.
Publicado: (2021)

TNF-α and RANKL promote osteoclastogenesis by upregulating RANK via the NF-κB pathway
por: Luo, Gang, et al.
Publicado: (2018)

Tectorigenin inhibits RANKL‐induced osteoclastogenesis via suppression of NF‐κB signalling and decreases bone loss in ovariectomized C57BL/6
por: Ma, Chiyuan, et al.
Publicado: (2018)

Acteoside Suppresses RANKL-Mediated Osteoclastogenesis by Inhibiting c-Fos Induction and NF-κB Pathway and Attenuating ROS Production
por: Lee, Seung-Youp, et al.
Publicado: (2013)

Agelasine D Suppresses RANKL-Induced Osteoclastogenesis via Down-Regulation of c-Fos, NFATc1 and NF-κB
por: Kang, Moo Rim, et al.
Publicado: (2014)

Puerarin inhibits titanium particle‐induced osteolysis and RANKL‐induced osteoclastogenesis via suppression of the NF‐κB signaling pathway
por: Tang, Wenkai, et al.
Publicado: (2020)

α-Mangostin inhibits LPS-induced bone resorption by restricting osteoclastogenesis via NF-κB and MAPK signaling
por: Zhang, Wenkan, et al.
Publicado: (2022)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
por: Yang, Xue, et al.
Publicado: (2021)

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
por: Qi, Dahu, et al.
Publicado: (2021)

BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Cai, Chenhui, et al.
Publicado: (2021)

Carnosol inhibits osteoclastogenesis in vivo and in vitro by blocking the RANKL-induced NF-κB signaling pathway
por: Cai, Pan, et al.
Publicado: (2022)

KMUP-1 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss: Roles of MAPKs, Akt, NF-κB and Calcium/Calcineurin/NFATc1 Pathways
por: Liou, Shu-Fen, et al.
Publicado: (2013)

Regulation of Osteoclastogenesis and Bone Resorption by miRNAs
por: Inoue, Kazuki, et al.
Publicado: (2021)

A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways
por: Liu, Ying, et al.
Publicado: (2021)

Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation
por: Kong, Xiangying, et al.
Publicado: (2015)

Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL
por: Kassem, Ali, et al.
Publicado: (2016)

Suppressive effects of (-)-tubaic acid on RANKL-induced osteoclast differentiation and bone resorption
por: Lim, Soomin, et al.
Publicado: (2023)

Corilagin suppresses RANKL‐induced osteoclastogenesis and inhibits oestrogen deficiency‐induced bone loss via the NF‐κB and PI3K/AKT signalling pathways
por: Lu, Jinwei, et al.
Publicado: (2020)

Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways
por: Feng, Wei, et al.
Publicado: (2017)

Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-κB Activation, and IκBα Degradation
por: Qin, Shengnan, et al.
Publicado: (2015)

Correction to: Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation
por: Kong, Xiangying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5pqr4bsqi5s1u89nnailv9d938